Fibroelastomas (FE) are described as small benign tumors incorporating avascular, papillary, and pedunculated tissue surrounded by a single covering of endothelium.1 Cardiac FE are relatively rare clinical entities. These pathologic tissues tend to be found incidentally on routine clinical imaging, with most patients asymptomatic at the time of diagnosis.1,2 However, individuals with FE on occasion may be predisposed to an increased risk of embolization with significant morbidity and mortality, hence diagnosis and management of this clinical condition remains of noteworthy interest. Whereas most cases tend to be attached to the aortic and mitral valves, nonvalvular locations have been described in a handful of case studies.3,4,5,6 FE may share common clinical features to thrombi, vegetations, or other tumors, so differentiating these etiologies can be a diagnostic challenge. Whereas isolated aortic thrombi may resolve with conservative anticoagulation, FE likely require surgical excision to reduce the risk of systemic embolization.3,7
This report describes a large ascending aortic wall fibroelastoma and provides a case-based review of the pathophysiology and treatment approach of this clinical condition.
A 77-year-old woman with a medical history of hypertension, type 2 diabetes mellitus, tobacco use, chronic obstructive pulmonary disease, and recent diagnosis of paroxysmal atrial fibrillation presented for an outpatient cardiac evaluation with complaints of gradually progressive dyspnea on exertion and chest heaviness. The patient was initiated on anticoagulation, given apixaban 5 mg twice daily for a week for paroxysmal atrial fibrillation (AF) prior to the clinical visit.
The patient was hemodynamically stable on presentation. The electrocardiogram revealed rate-controlled AF without signs of acute ischemia or infarction. Physical examination was largely unremarkable except for mild wheezing. Given significant risk factors for coronary artery disease, coronary computerized tomography angiogram (CCTA) and transthoracic echocardiogram (TTE) were obtained. The TTE was largely unremarkable except for mild left atrial enlargement. CCTA revealed extensive multivessel coronary artery calcification, including severe proximal left anterior descending artery (LAD) and proximal right coronary artery (RCA) stenosis in addition to an incidental finding of a significant area of hypoattenuation in the ascending thoracic aorta, near the coronary ostia, which was radiographically most likely consistent with a pedunculated aortic thrombus (Figures 1, 2 A-C).
Cardiac catheterization with coronary angiography was delayed given the proximity of the lesion to the coronary ostia and the potential risk for clot dislodgement and embolism. The patient was continued on full-dose anticoagulation with apixaban for another 2 weeks before subsequently repeating a magnetic resonance angiogram (MRA), which demonstrated no clear evidence of the aortic lesion previously noted on the CCTA. The hypercoagulable panel, including factor V Leiden, lupus anticoagulant, homocysteine levels, and a methylenetetrahydrofolate reductase homozygous gene mutation panel were unremarkable.
Assuming resolution of a possible aortic wall thrombus, a diagnostic coronary angiography was performed, which confirmed the presence of severe two-vessel coronary artery disease involving the proximal LAD and proximal RCA. Subsequently, the patient was referred for an elective surgical revascularization. Anticoagulation was continued, and she was evaluated by hematology. A repeat thorax/abdomen/pelvis CTA was requested by hematology, which again showed multiple filling defects within the ascending thoracic aorta. The largest one measured approximately 9 mm and was best visualized along the left side of the ascending thoracic aorta with a portion in proximity to the left coronary ostium. An intraoperative transesophageal echocardiogram (TEE) during elective surgical revascularization scheduled 1 month later still demonstrated a mobile mass in the ascending aorta, which was concerning for a grade 4 mobile atheroma, or thrombus, or an aortic tumor (Figure 3 A, B). She underwent two-vessel bypass surgery with left internal mammary artery to LAD and saphenous vein graft to distal right coronary artery (RCA) utilizing a y-shaped graft and hemiarch replacement using a Hemashield aortic graft (Getinge).
The removed ascending aorta was sent for further evaluation in three separate pieces measuring 1.5 × 0.8 × 0.2 cm to 11 × 3.8 × 0.3 cm. Separate specimen analysis of friable granular papillary intimal surface quantified as 0.2 × 0.2 × 0.1 cm to 1.1 × 0.8 × 0.2 cm with pink tan to yellowish discoloration and some focal areas of calcification (Figure 4 A). Although the mass morphologically had the appearance of a sea anemone similar to a myxoma, the histopathology with CD34 and Verhoeff–Van Gieson/EVG stains highlighted the elastic cores confirming the diagnosis of aortic wall fibroelastoma (Figure 4 B–D).
On outpatient clinical follow-up, the patient demonstrated a significant interval improvement in her cardiac symptoms.
Our case study describes a patient who presented with progressive dyspnea who was initially treated for incidental primary aortic thrombus but was later found to have an extremely rare incidence of nonvalvular aortic wall papillary FE. In a retrospective cohort analysis by Gowda et al., usual locations of papillary FE were the aortic (36%), mitral (29%), tricuspid (11%), and pulmonary (7%) valves.8 FE located on the aortic wall are particularly unusual and, to the best of our knowledge, have only been described three times previously.4,5,6
Whereas FE is uncommon, it is a significant source of noncardiogenic emboli with a high rate of complications; thus, timely diagnosis and management is essential to reduce adverse events. It is believed that the incidence of papillary FE was previously underestimated until recent advancements in imaging modalities.3 Our case in particular underscores the importance of multimodality imaging in establishing a successful clinical diagnosis. Whereas TEE helps provide initial characteristics regarding FE, including location and mobility, CTA and MRA can supply additional detail, including high-resolution 3-dimensional imaging, which allows further characterization of the aortic mass.9
Although CTA and TEE allowed the visualization of the aortic FE in our patient, subsequent MRA did not allow a clear visualization of the pathology. While MRA usually has a good sensitivity and specificity for diagnosis of aortic lesions, it has lower spatial resolution compared to CTA. Its contrast resolution also may be dependent on other factors, including the tissue-pathology interface, and such factors may have played a role in inadequate diagnosing of the aortic pathology earlier in our case. In addition to these factors, technical factors such as a suboptimal acquisition technique are possible. This case further underscores the importance of multimodality cardiovascular imaging in challenging cases.
The ideal management approach continues to be debated and is not well-established in the literature, especially for incidental FEs.10 In patients presenting with embolic strokes who have acceptable operative risk, excision of the lesions at highly experienced surgical centers has been the standard of care. In addition, the excision of papillary FE through minimally invasive approaches has been described. In patients who have high surgical risk, use of anticoagulation should be considered to prevent emboli from superimposed thrombi on the tumor.1,3,6,7,8,9,10
In our patient, symptoms of dyspnea were most likely due to the presence of underlying two-vessel significant coronary artery disease. However, gross surgical evaluation revealed the mass to be larger in size than first attributed by CT while also in proximity to the coronary ostium. Thus, clinical symptoms may have been exacerbated by intermittent obstruction of the coronary flow, caused by the papillary FE itself at the ostial level, as also evidenced by the small contrast filling defect on axial CT images at the levels across and in close proximity to the left coronary ostium (Figure 2 B, C).
Surgical intervention within our case also may have prevented a potential catastrophic embolic coronary blockade. This possible sequalae has been reported previously by Rolf et al. in a case of acute myocardial infarction from coronary embolization of an aortic FE of the thoracic ascending aorta.4
Our case study highlights an extremely rare yet very important diagnosis that should be considered in the differential diagnosis of patients with a primary aortic mass.
Diagnosis and management of cardiovascular tumors such as primary aortic FE remain challenging. Use of multimodality imaging can aid in the diagnosis and clinical management of these patients and also may prevent unwanted adverse events. In patients with symptomatic tumors, surgical resection ideally should be performed at cardiac centers with special expertise. However, management of asymptomatic or incidentally diagnosed papillary FE remains controversial, and shared clinical decision with use of multidisciplinary evaluation is highly recommended.
The authors would like to thank the department of pathology at WMC and especially Dr. Priti Chamdal for her assistance with histopathology slides.
The authors have no competing interests to declare.
Eftekhari H, Islam A, Slawsky M. Aortic valve fibroelastoma presenting with myocardial infarction. Catheter Cardiovasc Interv. 2011 Apr 1;77(5):716-9. doi: https://doi.org/10.1002/ccd.22879
Lak HM, Kerndt CC, Unai S, Maroo A. Cardiac papillary fibroelastoma originating from the coumadin ridge and review of literature. BMJ Case Rep. 2020 Aug 26;13(8):e235361. doi: https://doi.org/10.1136/bcr-2020-235361
Sun JP, Asher CR, Yang XS, et al. Clinical and echocardiographic characteristics of papillary fibroelastomas: a retrospective and prospective study in 162 patients. Circulation. 2001 Jun 5;103(22):2687-93. doi: https://doi.org/10.1161/01.cir.103.22.2687
Rolf T, Iglesias JF, Tozzi P, von Segesser LK. Acute myocardial infarction caused by coronary embolization of a papillary fibroelastoma of the thoracic ascending aorta. Interact Cardiovasc Thorac Surg. 2010 Nov;11(5):676-7. doi: https://doi.org/10.1510/icvts.2010.244772
Said SM, Ehlers HC, Hauptmann S, Hofmann S, Prondzinsky R. Papillary fibroelastoma of the aorta. Arch Cardiovasc Dis. 2008 Nov-Dec;101(11-12):805-6. doi: https://doi.org/10.1016/j.acvd.2008.05.015
Al-Azizi KM, Hamandi M, Baxter R, et al. Papillary Fibroelastoma of the Ascending Aorta. J Investig Med High Impact Case Rep. 2019 Jan-Dec;7:2324709619840377. doi: https://doi.org/10.1177/2324709619840377
Bowdish ME, Weaver FA, Liebman HA, Rowe VL, Hood DB. Anticoagulation is an effective treatment for aortic mural thrombi. J Vasc Surg. 2002 Oct;36(4):713-9. PMID: 12368731. doi: https://doi.org/10.1067/mva.2002.127968
Gowda RM, Khan IA, Nair CK, Mehta NJ, Vasavada BC, Sacchi TJ. Cardiac papillary fibroelastoma: a comprehensive analysis of 725 cases. Am Heart J. 2003 Sep;146(3):404-10. doi: https://doi.org/10.1016/S0002-8703(03)00249-7
Sharma R, Golian M, Shah P, Jassal DS, Shaikh N. Multimodality cardiac imaging of a left ventricular papillary fibroelastoma: a case report. BMC Res Notes. 2017 Jan 7;10(1):25. doi: https://doi.org/10.1186/s13104-016-2323-9
Chhabra L, Joshi S, Chaubey VK, Kaul S. Incidental cardiac papillary fibroelastoma: a management dilemma. BMJ Case Rep. 2013 Aug 7;2013:bcr2013200133. doi: https://doi.org/10.1136/bcr-2013-200133